Apalutamide, also known as ARN-509 and JNJ-56021927 , is an androgen receptor antagonist with potential antineoplastic activity. ARN-509 binds to AR in target tissues thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes. This ultimately inhibits the expression of genes that regulate prostate cancer cell proliferation and may lead to an inhibition of cell growth in AR-expressing tumor cells.
Androgen Receptor Inhibitors Related Products:
Chlormadinone acetate; Bicalutamide; Galeterone; Cyproterone acetate; AZD-3514; Spironolactone; ARV-110; Darolutamide; Megestrol Acetate; Clascoterone; RU-58841; Enzalutamide